Last reviewed · How we verify
HEC113995PA•H2O tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HEC113995PA•H2O tablet (HEC113995PA•H2O tablet) — Sunshine Lake Pharma Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HEC113995PA•H2O tablet TARGET | HEC113995PA•H2O tablet | Sunshine Lake Pharma Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HEC113995PA•H2O tablet CI watch — RSS
- HEC113995PA•H2O tablet CI watch — Atom
- HEC113995PA•H2O tablet CI watch — JSON
- HEC113995PA•H2O tablet alone — RSS
Cite this brief
Drug Landscape (2026). HEC113995PA•H2O tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/hec113995pa-h2o-tablet. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab